re: Ann: 2009 Preliminary Final Report and An...
I love it! What a great day for Biota (err, apart from the price!).
Got to love the fact that they are earning so much cash and yet have an explosive pipeline of products.
HCV got a mention (it's been quiet for ages) so hopefully they can get a candidate compound selected and move to phase I. May trigger a small milestone.
Heavy words on both LANI and HRV licensing. There must be much interest in these drugs and will be along with Relenza royalties the drivers in value.
I can't wait to see what other illnesses join the pipe, hopefully they buy a few more from universities and research houses, they are the ones with the latest science and keen professors!
What else to say, a fantastic year for Biota and well done to the management team.
...October royalties just around the corner.
BTA Price at posting:
$1.90 Sentiment: Buy Disclosure: Held
